<DOC>
	<DOCNO>NCT00095576</DOCNO>
	<brief_summary>This study test safety efficacy investigational Human Immunodeficiency Virus ( HIV ) vaccine . Efficacy measure either prevention HIV infection control HIV viral load subject become HIV infected . On September 18 , 2007 Protocol V520-023 DSMB ( Data &amp; Safety Monitoring Board ) review data plan interim analysis . These data demonstrate investigational vaccine candidate effective , vaccination study halt . Participants encourage continue come clinic schedule visit ongoing risk reduction counsel since vaccine effective .</brief_summary>
	<brief_title>Investigation V520 HIV Vaccine Proof-of-Concept Study ( V520-023 )</brief_title>
	<detailed_description>No treatment give V520-023 , however participant follow . V520-023 protocol end earlier originally plan per protocol participant ( HIV infect uninfected ) option participate observational long term follow protocol call V520-030/HVTN 504 , serve extension V520-023 would continue end 2009 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy , HIV seronegative adult high risk acquire HIV infection Can previously receive investigational vaccine In monogamous relationship HIV1 seronegative partner &gt; 1 year History anaphylaxis and/or allergy vaccine component , include Tris buffer , MgCl2 , polysorbate 80 ( TWEEN ) Received immune globulin blood derive product 3 month injection first dose vaccine/placebo schedule within 14 day injection Previously vaccinate live virus vaccine within 30 day injection first dose vaccine schedule within 14 day injection Previously vaccinate inactivated vaccine within 5 day injection first dose vaccine schedule within 14 day injection Known history immunodeficiency History malignancy ( exception ) Contraindication intramuscular ( IM ) injection anticoagulant therapy thrombocytopenia Female subject pregnant breast feeding , expect conceive donate egg Week 30 study Male subject plan impregnate provide sperm donation Week 30 study Previously receive investigational HIV vaccine Has active drug alcohol abuse dependence would interfere adherence study requirement , endanger subject 's health study Has condition might endanger subject 's health interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>